作者
Damian Smedley,Katherine R. Smith,Antonio Martin,Ellen A. Thomas,Ellen M. McDonagh,Valentina Cipriani,Jamie M. Ellingford,Gavin Arno,Arianna Tucci,Jana Vandrovcova,Georgia Chan,Hywel J. Williams,Thiloka Ratnaike,Wei Wei,Kathleen Stirrups,Kristina Ibanez,Loukas Moutsianas,Matthias Wielscher,Anna Need,Michael R. Barnes,Letizia Vestito,James Buchanan,Sarah Wordsworth,Sofie Ashford,Karola Rehmström,Emily Li,Gavin Fuller,Philip Twiss,Olivera Spasic-Boskovic,Sally Halsall,R. Andres Floto,Kenneth E. S. Poole,Annette G. Wagner,Sarju G. Mehta,Mark Gurnell,Nigel Burrows,Roger F.L. James,Christopher Penkett,Eleanor Dewhurst,Stefan Gräf,Rutendo Mapeta,Mary Kasanicki,Andrea Haworth,Helen Savage,Melanie Babcock,Martin G. Reese,Mark Bale,Emma Baple,Christopher Boustred,Helen Brittain,Anna de Burca,Marta Bleda,Andrew Devereau,Dina Halai,Eik Haraldsdottir,Zerin Hyder,Dalia Kasperaviciute,Christine Patch,Dimitris Polychronopoulos,Angela Matchan,Razvan Sultana,Mina Ryten,Ana L.T. Tavares,Carolyn Tregidgo,Clare Turnbull,Matthew Welland,Suzanne Wood,Catherine Snow,Eleanor Williams,Sarah Leigh,Rebecca E. Foulger,Louise C. Daugherty,Olivia Niblock,Ivone U.S. Leong,Caroline F. Wright,James O.J. Davies,Charles Crichton,James Welch,Kerrie Woods,Lara Abulhoul,Paul Aurora,Detlef Bockenhauer,Alexander Broomfield,Maureen Cleary,Tanya Lam,Mehul T. Dattani,Emma Footitt,Vijeya Ganesan,Stephanie Grunewald,Sandrine Compeyrot-Lacassagne,Francesco Muntoni,Clarissa Pilkington,Rosaline Quinlivan,Nikhil Thapar,Colin Wallis,Lucy R. Wedderburn,Austen Worth,Teofila Bueser,Cecilia Compton,Charu Deshpande
摘要
BACKGROUND The U.K. 100,000 Genomes Project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases after usual care and the alignment of this research with health care implementation in the U.K. National Health Service. Other parts of this project focus on patients with cancer and infection. METHODS We conducted a pilot study involving 4660 participants from 2183 families, among whom 161 disorders covering a broad spectrum of rare diseases were present. We collected data on clinical features with the use of Human Phenotype Ontology terms, undertook genome sequencing, applied automated variant prioritization on the basis of applied virtual gene panels and phenotypes, and identified novel pathogenic variants through research analysis. RESULTS Diagnostic yields varied among family structures and were highest in family trios (both parents and a proband) and families with larger pedigrees. Diagnostic yields were much higher for disorders likely to have a monogenic cause (35%) than for disorders likely to have a complex cause (11%). Diagnostic yields for intellectual disability, hearing disorders, and vision disorders ranged from 40 to 55%. We made genetic diagnoses in 25% of the probands. A total of 14% of the diagnoses were made by means of the combination of research and automated approaches, which was critical for cases in which we found etiologic noncoding, structural, and mitochondrial genome variants and coding variants poorly covered by exome sequencing. Cohortwide burden testing across 57,000 genomes enabled the discovery of three new disease genes and 19 new associations. Of the genetic diagnoses that we made, 25% had immediate ramifications for clinical decision making for the patients or their relatives. CONCLUSIONS Our pilot study of genome sequencing in a national health care system showed an increase in diagnostic yield across a range of rare diseases. (Funded by the National Institute for Health Research and others.).